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Abstract Vascular endothelial growth factor (VEGF) is a po-
tent angiogenic mediator in tissue repair. In non-healing human
wounds plasmin cleaves and inactivates VEGF165. In the present
study, we generated recombinant VEGF165 mutants resistant to
plasmin proteolysis. Substitution of Arg110 with Ala110 or
Gln110, and Ala111 with Pro111 yielded plasmin-resistant and
biologically active VEGF165 mutants. In addition, substitution
of Ala111 with Pro111 resulted in a substantial degree of stabi-
lization when incubated in wound £uid obtained from non-heal-
ing wounds. These results suggest that the plasmin cleavage site
Arg110/Ala111 and the carboxyl-terminal domain play an im-
portant role in the mitogenic activity of VEGF165.
, 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Vascular endothelial growth factor (VEGF) is an endothe-
lial cell-speci¢c multifunctional cytokine that is a key regula-
tor in physiologic and pathologic processes of angiogenic re-
modeling (reviewed in [1]). By di¡erential mRNA splicing, the
single human VEGF gene gives rise to at least six protein
isoforms VEGF121; 145; 165; 183; 189, and 206 [2,3]. Among them,
the 165-amino-acid isoform is the major gene product found
in human tissues. The splice variants di¡er primarily in the
presence or the absence of the heparin-binding domains en-
coded by exons 6 and 7, giving rise to forms that di¡er in their
heparin/heparan-sulfate binding ability, as well as their a⁄n-
ities to VEGF receptors £t-1, £k-1/KDR and neuropilin-1 [4^
9]. Whereas VEGF121 does not bind heparan-sulfate and is
freely di¡usible, VEGF189 binds heparin and is primarily as-
sociated with the cell surface and extracellular matrix, and
VEGF165 has intermediate properties [5,10,11]. Further, native
VEGF189 binds to £t-1 but not £k-1/KDR [12]. Native
VEGF189 requires maturation by urokinase (uPA) within the
exon 6 encoded sequence to bind to £k-1/KDR and to exert a
mitogenic e¡ect on endothelial cells [12]. In contrast, plasmin
digestion of VEGF165 decreases its mitogenic activity for en-
dothelial cells [13]. Plasmin digestion of VEGF165 yields two
fragments: an amino-terminal homodimer (VEGF1-110) con-
taining the £t-1 and the £k-1/KDR receptor binding determi-
nants encoded by exons 3 and 4, respectively, and a carboxyl-
terminal polypeptide comprising the neuropilin-1 binding site
encoded by exon 7 (VEGF111-165) [13]. Interestingly, the
reduced mitogenic activity of the amino-terminal homodimer
VEGF1-110 is similar to that observed for VEGF121 [12,13].
These ¢ndings suggest that di¡erential protease susceptibility,
extracellular localization and/or receptor binding may result
in distinct functions for di¡erent VEGF isoforms.
Recently, we demonstrated that the proteolysis of VEGF165
by plasmin is increased in wound £uid collected from chronic
non-healing wounds versus healing wounds [14]. VEGF plays
a critical role during the angiogenic response in tissue repair
[15^17], suggesting that VEGF degradation and loss of its
biological activity may contribute to an impaired wound heal-
ing response. These results prompted us to introduce amino
acid alterations at the plasmin sensitive cleavage site of
VEGF165 (Arg110/Ala111), in order to stabilize the VEGF165
molecule. Substitutions at either site result in VEGF165 prod-
ucts that, while maintaining growth-promoting properties, are
either fully or partially plasmin-resistant. This type of modi-
¢cation would be expected to increase the period that topi-
cally applied VEGF protein is active in the wound environ-
ment, implying a potential clinical application.
2. Materials and methods
2.1. Site-directed mutagenesis
Mutagenesis was performed using base mismatched oligonucleoti-
des as indicated: MutAla110 5P-GACCAAAGAAAGATGCCGCAAG-
ACAAG-3P, MutGln110 5P-GACCAAAGAAAGATCAG GCAAGAC-
AAG-3P, MutPro111 5P-GACCAAAGAAAGATAGACCAAGACAA-
G-3P, MutLys110Pro111 5P-GACCAAAGAAAGATAAGCCAAGACA-
AG (nucleotide di¡erences between VEGF165-Wt and mutants are
indicated in bold) (MWG-Biotech, Ebersberg, Germany). VEGF165
mutants were generated using the Gene Editor1 in vitro site-directed
mutagenesis system (Promega, Mannheim, Germany). VEGF165 mu-
tants were characterized by DNA sequencing using the ABI Prism1
Big Dye1 terminator cycle sequencing ready reaction kit (PE Applied
BioSystems, Langen, Germany) and con¢rmed in both the 5P and the
3P direction.
2.2. Cell culture
COS-1 cells (provided by Dr. Ingo Flamme, ZMMK, Cologne,
Germany) were cultured in Dulbecco’s modi¢ed-Eagle’s medium
(DMEM) containing 10% fetal calf serum (FCS), L-glutamine
(2 mM) and penicillin (10 U/ml) streptomycin (10 Wg/ml). Human
umbilical venous endothelial cells (HUVEC; TEBU, Frankfurt, Ger-
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many) were maintained in MCDB 131 (Life Technologies, Eggenstein,
Germany) supplemented with 8% FCS, 20 mM glutamine, penicillin
(10 U/ml), streptomycin (10 Wg/ml) and ECGS/H growth supplement
(PromoCell, Freiburg, Germany).
2.3. Puri¢cation of VEGF165-protein
COS-1 cells were transfected using the Superfect transfection re-
agent (Qiagen, Hilden, Germany) following the manufacturer’s in-
structions and cultivated in serum free medium (DMEM containing
2 mM L-glutamine, penicillin 10 U/ml, streptomycin 10 Wg/ml and ITS
supplement) (Sigma, Deisenhofen, Germany). Conditioned medium
(200 ml) was collected following 48 h and incubated for 4 h with
5 ml of heparin-sepharose (Pharmacia, Freiburg, Germany) at 4‡C.
The heparin-sepharose was packed in a column and culture medium
was loaded onto the column at a £ow rate of 25 ml/h. Elution of
bound proteins was carried out by 10 mM Tris^HCl, 0.9 M NaCl pH
7.2. Fractions were pooled, desalted (D-Salt1 Excellulose1 Plastic
Desalting Columns, Pierce, St. Augustin, Germany), lyophilized and
the concentration of VEGF165 was determined using a commercially
available human VEGF-speci¢c ELISA (RpD Systems, Minneapolis,
MN, USA). The assay was performed following the manufacturer’s
instructions.
2.4. SDS^PAGE and immunoblotting
SDS^PAGE was performed following the protocol of Laemmli.
Purchased recombinant human VEGF165 (rVEGF165 ; RpD Systems,
Minneapolis, MN, USA) and VEGF165 expressed in COS-1 cells were
incubated at 37‡C (pH 7.6, up to 4 h) with wound £uid obtained from
non-healing wounds, plasmin solution (0.01 U/ml; human plasma
plasmin, Sigma, Deisenhofen, Germany) or as a negative control
with PBS. Reactions were terminated by the addition of Pefabloc0
(1 mM ¢nal concentration), and frozen at 320‡C before analysis by
SDS^PAGE or MALDI-TOF-mass-spectrometry. For Western blot-
ting fragments were resolved on 12% non-reducing SDS^PAGE gels
and transferred to nitrocellulose (Hybond C-super, Amersham).
VEGF165 integrity was determined by detecting immunoreactive prod-
ucts with a polyclonal rabbit antibody that recognizes the amino-
terminal VEGF epitopes (raised against a 20-amino-acid amino-ter-
minal peptide; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Detection of intact and VEGF-derived degradation products was ac-
complished using the LumiLight plus chemiluminescence detection
system (Roche Diagnostics, Mannheim, Germany). Densitometric
analysis of Western blots was performed using a FluroS-Multiimager
and Quantity one analysis-software (Biorad, Munich, Germany).
2.5. Protein sequencing
Protein sequencing was performed by Dr. Karlheinz Mann (Max-
Planck-Institute of Biochemistry, Martinsried, Germany). For amino-
terminal sequencing the PAGE-separated fragments were blotted onto
Immobilon-P (Millipore, Bedford, MA, USA) according to Matsu-
daira [18]. Sequencing was done using the Applied BioSystems Procise
492 sequencer.
2.6. MALDI-TOF mass spectrometry
The mass spectrometry analysis of plasmin-induced VEGF degra-
dation was performed by Dr. Macht in the Center of Molecular Med-
icine Cologne. For the detection of high molecular weight proteins a
voltage of 20kV was used. The analysis of small molecular weight
proteins was performed using a post source decay mass spectrometry
(PSD-MS) with a voltage of 26.3 kV and a re£ector-voltage of 22.5
kV.
2.7. Endothelial cell proliferation assay for VEGF
HUVECs were seeded in 96-well plates (4U103 cells/well) in growth
medium. After a starvation phase of 16 h (1% FCS), cells were stimu-
lated by VEGF variants (1 to 15 ng/ml) for 5 days. Cell proliferation
was assessed using a BrdU-based proliferation assay (Roche Diagnos-
tics). VEGF-mediated mitogenic activity was inhibited by adding a
speci¢c VEGF-neutralizing polyclonal goat antiserum (50 Wg/ml)
(RpD Systems). Three separate dose response experiments were per-
formed. Di¡erences between wild type and mutant proteins were an-
alyzed using the unpaired t-test.
2.8. Wound £uid
Wound £uid was obtained from three di¡erent patients su¡ering
from non-healing wounds due to venous insu⁄ciency (ulcers showed
no clinical sign of infection, 25^50 cm2 in size, mean age of patients 67
years). Ulcers were covered with a semi-permeable polyurethane ¢lm
(Hyalo¢lm0, Hartmann; Heidenheim, Germany). Following collec-
tion, £uids were centrifuged (10 min, 13 000Ug, 4‡C) and superna-
tants were frozen at 380‡C until use.
3. Results
Plasmin-mediated degradation of VEGF165 was assessed us-
ing VEGF165 protein either puri¢ed from COS-1 cell condi-
tioned media (VEGF165-Wt) or recombinant VEGF165 com-
mercially available and isolated from a baculovirus expression
system (VEGF165-Wt, RpD). As indicated by Western blot-
ting baculovirus-expressed VEGF165 appeared on SDS^PAGE
as a single 42-kDa protein band (Fig. 1A, lanes 1^5), while
VEGF165 expressed in COS-1 cells appeared as a 42/45-kDa
protein doublet (Fig. 1A, lanes 6^10). Generation of this dou-
blet is due to protein glycosylation in the eukaryotic system.
However, this posttranslational modi¢cation does not a¡ect
the protein’s biological activity (Dr. Ingo Flamme, personal
communication). Amino-terminal sequencing of VEGF165
fragments obtained following plasmin digestion gave four
VEGF165 fragments. Based on the sequence-ARQENP(C)GP
the most N-terminal-proximal cleavage site was identi¢ed as
Arg110/Ala111 (data not shown). Other cleavage sites were
between Arg123/Arg124, Lys125/His126, and Lys147/Ala148.
The cleavage site Arg110/Ala111 was con¢rmed by MALDI-
TOF analysis of digestion products (data not shown). In ad-
dition, the amino-terminal fragment VEGF1-110 could be de-
tected as a 38-kDa fragment by Western blotting (Fig. 1A).
Oligonucleotide primer-directed mutagenesis was used to
generate VEGF165 mutants. Arg110 was changed to either
Ala or Gln, and Ala111 to Pro. To test the stability of these
mutants, proteins were incubated with plasmin and the deg-
radation analyzed by Western blotting. Comparable to the
COS-1-derived VEGF165-Wt, all VEGF mutants appeared
on SDS^PAGE as a 42/45 kDa protein doublet (Fig. 1B).
In contrast to the susceptibility of VEGF165-Wt to plasmin
proteolysis, the electrophoretic mobility of the mutant pro-
teins remained stable over the 240 min incubation period
(Fig. 1B, lanes 1^17). VEGF165-Wt remained stable when in-
cubated at 37‡C in bu¡er alone (Fig. 1B, lanes 18, 19).
Next, the mitogenic activity of each VEGF variant was
assessed using a BrdU proliferation assay on HUVE cells.
All mutant VEGF165 proteins exhibited a dose-dependent
stimulation of BrdU incorporation in HUVE cells and the
activity of mutant proteins did not show a clear statistical
di¡erence compared to the wild type protein (Fig. 2). Mito-
genic activity of wild type and mutant VEGF165 proteins was
inhibited by addition of a neutralizing polyclonal antibody to
hVEGF (data not shown).
BrdU proliferation assay was used to assess the mitogenic
activity of plasmin-digested VEGF165 proteins on HUVECs.
Plasmin-digestion of VEGF165-Wt, either COS-1-derived or
purchased, reduced its stimulatory e¡ect approximately 40
and 60% following a 90 or 240-min incubation in plasmin,
respectively (Fig. 3A, B). In contrast, plasmin did not a¡ect
the mitogenic potency of VEGF mutants MutAla110 and
MutPro111 at any of the time points assessed (Fig. 3C,D).
The mitogenic activity of VEGF-Wt protein and mutant
VEGF proteins incubated at 37‡C in bu¡er alone was stable.
To assess the stability of VEGF variants under more clin-
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ically relevant conditions, wild type and mutant VEGF165
proteins were incubated in wound £uid collected from patients
su¡ering from non-healing wounds. In accordance with pre-
vious studies, incubation of VEGF165 in wound £uid obtained
from non-healing wounds resulted in the degradation of the
42/45 kDa proteins into a fragment of approximately 38 kDa
(Fig. 4A). Interestingly, one of the mutant proteins remained
stable when incubated in wound £uid obtained from non-
healing wounds. The insertion of a neutral, non-cyclic amino
acid at position 110 (MutAla110 and MutGln110) leads to a deg-
radation pattern similar to the wild type proteins ^ the 42/45
kDa doublet produced a single 38-kDa fragment (Fig. 4B,
lanes 5^8, lanes 13^16). In contrast, substitution of alanine
at position 111 with the neutral and cyclic amino acid proline
produced a unique result. As indicated by Western blot, the
42/45-kDa doublet remained stable in the presence of wound
£uid over the 1-h incubation period (Fig. 4B, lanes 1^3, lanes
9^11). Prolonged incubation of MutPro111/MutLys110-Pro111 up
to 240 min led to a protein smear over 45 and 38 kDa (Fig.
4B, lanes 4, 12). The stability of MutPro111 and the degrada-
tion pattern of MutAla110 and MutGln110 proteins were consis-
tent in wound £uids obtained from three di¡erent patients.
Western blots of VEGF165-Wt protein and MutLys110-Pro111
protein digested in wound £uid were analyzed by scanning
densitometry (Fig. 4C).
4. Discussion
In the present study, we elucidated the functional role of the
plasmin cleavage site Arg110/Ala111 in the VEGF165 molecule
for its mitogenic potency. Western blot analysis, amino-termi-
nal sequencing and MALDI-TOF analysis of plasmin-digested
VEGF165 fragments identi¢ed Arg110/Ala111 as the plasmin
cleavage site closest to the N-terminus of the molecule. Incu-
bation of VEGF165 in plasmin for 4 h reduced its mitogenic
potency on HUVE cells by over 50%. This data suggests a
Fig. 1. Commercially available VEGF165 (VEGF165-Wt, RpD) (A,
lanes 1^5), wild type VEGF165 expressed in COS-1 cells (VEGF165-
Wt) (A, lanes 6^10), and VEGF165 mutations MutAla110 (B, lanes
1^5), MutPro111 (B, lanes 6^9), MutGln110 (B, lanes 10^13) and
MutLys110Pro111 (B, lanes 14^17) were incubated in plasmin for the
indicated time periods. VEGF165-Wt incubated in bu¡er alone (B,
lanes 18 and 19) served as control. VEGF165 degradation was moni-
tored by SDS^PAGE under non-reducing conditions and by detect-
ing immunoreactive products with a VEGF-speci¢c antibody that
recognizes the amino-terminal VEGF epitopes.
Fig. 2. HUVECs were cultured for 96 h in the presence of varying concentrations of VEGF165 variants expressed in COS-1 cells. BrdU incor-
poration in proliferating cells was determined by ELISA. Triplicate samples were assayed and results are shown RS.D.
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critical role of the plasmin cleavage site Arg110/Ala111 and
the carboxyl-terminal domain of VEGF165 in the stimulation
of endothelial cell proliferation.
VEGF activity is mediated through two receptors: £t-1 and
£k-1/KDR [4]. Both receptors show di¡erent kinase activity,
and have separate signal transduction properties and possibly
mediate di¡erent functions [4,19,20]. Receptor studies suggest
that the major positive signal of VEGF for endothelial pro-
liferation and vascular permeability appears through £k-1/
KDR, while that from £t-1 seems to contribute about one
tenth of the total signal [21,22]. Recently, Soker et al. have
identi¢ed a new VEGF receptor, neuropilin-1, that binds
VEGF165 but not VEGF121 [7]. When co-expressed in cells
with £k-1/KDR, neuropilin-1 enhanced the binding of
VEGF165 to £k-1/KDR and VEGF165-mediated chemotaxis
and proliferation [7,23]. Conversely, inhibition of VEGF165
binding to neuropilin-1 inhibits its binding to £k-1/KDR
and its mitogenic activity for endothelial cells. These ¢ndings
suggest that neuropilin-1 may present VEGF165 to the £k-1/
KDR receptor in a manner that enhances the e¡ectiveness of
£k-1/KDR-mediated signal transduction. VEGF165 binds to
neuropilin-1 via the VEGF exon 7 encoded peptide, which
comprises most of the heparin-binding site of VEGF165. The
Fig. 3. Commercially available VEGF165 (VEGF165-Wt, RpD) (A),
VEGF165-Wt expressed in COS-1 cells (VEGF165-Wt) (B), and mu-
tant VEGF165 proteins MutAla110 (C) and MutLys110Pro111 (D) were
incubated in plasmin for the indicated time (VEGF165 10 ng/ml).
Following plasmin incubation, the mitogenic potency of VEGF165
proteins was determined on HUVECs. BrdU incorporation in prolif-
erating cells was determined by ELISA. Statistical analysis was per-
formed with the unpaired t-test. Triplicate samples were assayed
and results are shown RS.D. (*P=0.0275, **P9 0.0084).
C
Fig. 4. VEGF165-Wt (A) and mutant VEGF165 proteins
MutLys110Pro111 (B, lanes 1^4), MutAla110 (B, lanes 5^8), MutPro111
(B, lanes 9^12) and MutGln110 (B, lanes 13^16) were incubated in
wound £uid collected from patients su¡ering from chronic non-heal-
ing wounds for time periods as indicated (patients n=3; representa-
tive Western blots are presented). VEGF165 degradation was moni-
tored by SDS^PAGE under non-reducing conditions and by
detecting immunoreactive products with a VEGF-speci¢c antibody
that recognizes the amino-terminal VEGF epitopes. C: Degradation
of VEGF165-Wt and MutLys110Pro111 protein incubated in chronic
wound £uid was monitored by analyzing the intensity of the 42/45
kDa signal by scanning densitometry, and is presented as a percent-
age of the signal intensity at timepoint 0. Statistical analysis was
performed with the unpaired t-test. Three Western blots were ana-
lyzed and results are shown RS.D. (*P=0.0055, **P=0.0082).
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ability of VEGF165 to bind neuropilin-1 may partly explain its
greater mitogenic potency relative to VEGF molecules missing
the exon 7 encoded peptides, whether due to proteolysis or
alternative splicing.
Recently we demonstrated that proteolysis and inactivation
of VEGF165 by plasmin is increased in wound £uid collected
from non-healing wounds versus healing wounds [14]. These
results prompted us to investigate whether VEGF165 could be
proteolytic stabilized by mutating the plasmin cleavage site
Arg110/Ala111. A general consensus sequence of the plasmin
cleavage site is not known. Alterations in amino acid residues
of VEGF165 were based on the notion that plasmin substrate
speci¢city is directed by its negatively charged catalytic do-
main. Therefore, Arg110 was substituted by a neutral, non-
polar, non-cyclic amino acid such as alanine or glutamine. We
also replaced Ala111 with proline, an amino acid change that
might be expected to have e¡ects on the tertiary as well as
primary structure of the protein. Western blot analysis and
cell proliferation assay demonstrated that both the replace-
ment of the Arg110 by a neutral, non-cyclic amino acid and
the introduction of Pro111 stabilized VEGF165 mitogenic ac-
tivity in the presence of plasmin. This data indicates that the
mutation of the Arg110/Ala111 site of VEGF165 dramatically
a¡ected its plasmin sensitivity.
Consistent with these observations, VEGF165 mutants were
temporarily stabilized when incubated with wound £uid ob-
tained from non-healing wounds. However, inactivation of the
plasmin cleavage site by a neutral, non-cyclic amino acid is
not su⁄cient to stabilize the VEGF165 molecule in the pres-
ence of wound £uid. In contrast, altering the plasmin cleavage
site by substituting VEGF-Ala111 with the cyclic VEGF-
Pro111 increases the VEGF stability in chronic wounds. These
results suggest that modi¢cation of the tertiary structure of
the VEGF165 protein can temporarily stabilize VEGF165 in the
wound £uid of non-healing wounds. However, a direct e¡ect
at the level of primary sequence recognition by proteases is
also possible.
Little is known about local mechanisms leading to and
perpetuating cutaneous wound healing failure. A disturbed
balance of proteolytic and anti-proteolytic activity character-
izes the hostile environment of a chronic wound [24,25]. The
failure of certain wounds to resolve successfully may be due to
the increased proteolytic degradation of regulatory factors,
including growth factors and extracellular matrix molecules
[14,26^28]. Increased degradation of topically applied growth
factors may also account for the discrepancy between the
remarkable e⁄cacy of growth factors in wound healing in
animal models and the rather disappointing clinical results
in non-healing wounds [14,27]. Hence, controlling the proteo-
lytic activity in the chronic wound environment might be a
key strategy to improve wound healing. Topical application of
proteolysis-resistant growth regulators in chronic wounds
might enhance the e⁄ciency of these mediators in the hostile
chronic wound environment.
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